Elevai Labs INC 8-K filings

PMGC Holdings Inc. has entered into a Securities Purchase Agreement for an equity line of credit up to $20 million, securing initial net proceeds of $3.99 million for general corporate purposes and potential acquisitions.

PMGC Holdings Inc. has increased its authorized share capital to 2.5 billion shares, comprising 2 billion common and 500 million preferred stock.

PMGC Holdings Inc. announced a 3.5-for-1 reverse stock split of its common stock, effective September 2, 2025, to reduce outstanding shares.

PMGC Holdings Inc. announced a warrant inducement agreement, raising $1.67 million by reducing the exercise price of existing warrants and issuing new unregistered warrants.

PMGC Holdings Inc. has amended consulting agreements for its Chairman and CEO, introducing significant acquisition-based compensation tied to deal value.

PMGC Holdings Inc. has terminated its electronics manufacturing acquisition letter of intent to strategically pivot its merger and acquisition efforts towards high-growth CNC machine shops in the aerospace, defense, and industrial sectors.

PMGC Holdings Inc. has completed the acquisition of AGA Precision Systems LLC, a California-based CNC machining business, adding $1.39 million in cash-flow-positive revenue and strengthening its U.S. manufacturing portfolio.

PMGC Holdings Inc. has completed the acquisition of Pacific Sun Packaging Inc. for $1,148,000 in cash and a contingent earnout, marking a strategic entry into the specialized IT and electronics packaging market.

PMGC Holdings Inc. has entered into a non-binding Letter of Intent to acquire a U.S.-based, AS9100and ISO 9001-certified CNC aerospace manufacturer with approximately $4.5 million in 2024 annual revenue and $500,000 in adjusted EBITDA.

PMGC Holdings Inc. announced a non-binding Letter of Intent to acquire a profitable U.S.-based CNC machine shop and its subsidiary, Northstrive Biosciences, initiated Phase II of its AI development program for cardiometabolic diseases.

PMGC Holdings Inc. announced it has signed a non-binding Letter of Intent to acquire a U.S.-based, cash-flow positive electronics contract manufacturing company with over 40 years of operational history.

Northstrive Biosciences, a subsidiary of PMGC Holdings, has entered into a second amendment to a license agreement with MOA Life Plus and a binding term sheet with Modulant Biosciences to expand the use of EL-22 in the animal health sector.

PMGC Holdings Inc. has entered into a Secondment Agreement with Northstrive Companies Inc. to secure employee services on a temporary basis.

Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., announces the filing of four new patent applications for its EL-22 and EL-32 programs targeting obesity and animal health.

Northstrive Biosciences, a subsidiary of PMGC Holdings, announced positive preliminary responses from the FDA regarding its clinical development plans for EL-22 in combination with GLP-1 receptor agonists for obesity treatment, supporting a potential Phase 2 clinical trial.

PMGC Holdings Inc. has entered into an agreement with Univest Securities, LLC to sell up to $100 million of its common stock through an at-the-market offering.

PMGC Holdings Inc. has signed a non-binding Letter of Intent to acquire a U.S.-based, cash-flow positive information technology custom packaging company.

Northstrive Biosciences, a subsidiary of PMGC Holdings, has partnered with Yuva Biosciences to develop novel pharmaceutical treatments for obesity and cardiometabolic diseases using YuvaBio's AI platform.

PMGC Holdings Inc. amends consulting agreements with Northstrive Companies Inc. and GB Capital Ltd, tying compensation to market valuation milestones and licensing agreements.

PMGC Holdings Inc. has amended its consulting agreements with its Non-Executive Chairman and Non-Employee CEO, introducing new milestone-based cash and equity bonus opportunities tied to market valuation, licensing agreements, and EBITDA targets.

PMGC Holdings Inc. has entered into a definitive agreement for a $1.48 million registered direct offering of common stock and pre-funded warrants priced at-the-market under Nasdaq rules.

PMGC Holdings Inc. announces the repurchase of shares and warrants from an existing shareholder in a privately negotiated transaction.

PMGC Holdings Inc. repurchased shares from two existing shareholders for approximately $52, signaling a potential strategic move in managing its equity.

PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to maintain compliance with Nasdaq listing requirements.

PMGC Holdings Inc. and INmune Bio, Inc. have mutually agreed to terminate their License Agreement, effective February 27, 2025.

PMGC Holdings Inc. filed amendments to its Series B Preferred Stock, increasing the authorized shares from 50 million to 300 million and clarifying the rights and preferences of the holders.

Northstrive Biosciences, a subsidiary of PMGC Holdings, has submitted a pre-IND meeting request to the FDA for EL-22, a potential obesity therapy.

Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., presented its obesity drug candidates, EL-22 and EL-32, at the UCLA Obesity Symposium.

PMGC Holdings Inc. finalized warrant inducement transactions, generating gross proceeds of $1.94 million before expenses.

PMGC Holdings Inc. has entered into a warrant inducement agreement, reducing the exercise price of existing warrants and issuing new warrants to purchase common stock.